Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Even though RevMed’s experimental pancreatic cancer drug, daraxonrasib, hasn’t yet achieved approval, it is available through an expanded access program. But that doesn’t mean getting it is easy.
Also, the FDA’s voucher program spearheaded by erstwhile chief Marty Makary could be in for a makeover.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
